Ranbaxy Adr Rises After Usfda Nod
On September 16, the news of Ranbaxy receiving the US FDA nod to market an oral suspension drug, Cephalexin, led to a major upswing in the company
Explore Business Standard
Explore Business Standard
On September 16, the news of Ranbaxy receiving the US FDA nod to market an oral suspension drug, Cephalexin, led to a major upswing in the company
First Published: Sep 17 2003 | 12:00 AM IST